SecurityCMD / Cantel Medical Corp
IndustrySurgical and Medical Instruments and Apparatus
Common Stock Shares Outstanding41,709,335 shares (as of 2018-04-30)
Total Insiders21
Total Directors12
Total Officers11

Stock Insider Trading (from SEC Form 4)

CMD / Cantel Medical Corp Insider Trades

Cantel Medical Corp insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

CMD / Cantel Medical Corp insiders include ANAYA STEVEN C, BATKIN ALAN R, Yellin Seth M, Diker Mark N., Donnelly-Brienza Dorothy A, Pronovost Peter, Conway Lawrence Forese Laura L, SLOVIN BRUCE, Clifford Peter G, EVNIN ANTHONY B, BERMAN ANN E, DIKER CHARLES M, COHEN JOSEPH M, Hansen Jorgen B, Capone Brian, Myers Ronnie, FOTIADES GEORGE L, NODIFF ERIC W, SHELDON CRAIG A, and Krakauer Andrew A, .

Insider Roster

Insider Dir Off 10% Shares Owned
X 6,984
Myers Ronnie Director
X 2,509
X 95,378
Diker Mark N. Director
X 471,834
Pronovost Peter Director
X 20,322
X 7,011
Forese Laura L Director
X 4,922
X 54,937
NODIFF ERIC W EVP and General Counsel
X 37,357
Clifford Peter G EVP and CFO
X 14,172
Capone Brian VP and Princ. Accounting Ofr
X 2,123
DIKER CHARLES M Chairman, Director, 10% Owner
X X X 3,681,511
Donnelly-Brienza Dorothy A SVP and Chief HR Officer
X 4,777
Yellin Seth M Executive Vice President
X 22,856
Conway Lawrence Senior Vice President
X 5,416
Hansen Jorgen B President and COO
X 47,520
ANAYA STEVEN C SVP; Chief Accounting Officer
X 36,928
Krakauer Andrew A CEO, Director

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Form Insider Code 10b-5 Direct Share
Post Value
2018-07-31 4 EVNIN ANTHONY B A D 712 6,984
2018-07-31 4 BATKIN ALAN R A D 712 54,937
2018-07-31 4 Forese Laura L A D 712 4,922
2018-07-31 4 BERMAN ANN E A D 712 7,011
2018-07-31 4 Pronovost Peter A D 712 20,322
2018-07-31 4 Diker Mark N. A D 712 471,834
2018-07-31 4 FOTIADES GEORGE L A D 712 95,378
2018-07-31 4 Myers Ronnie A D 712 2,509
2018-07-06 4 Myers Ronnie S D 95.718 -261 1,797 172,005
2018-05-15 4 NODIFF ERIC W F D 124.47 -2,197 37,357
2018-04-10 4 Myers Ronnie S D 108.261 -200 2,058 222,801
2018-04-17 4 Capone Brian F D 113.42 -173 2,123
2018-04-17 4 Clifford Peter G S D 114.8918 -1,250 14,172 1,628,247
2018-04-10 4 NODIFF ERIC W S D 108.3052 -1,275 39,556 4,284,120
2018-03-29 4 DIKER CHARLES M S D 111.7907 -5,070 3,681,511 411,558,692
2018-03-28 4 DIKER CHARLES M S D 110.6757 -4,246 3,686,581 408,014,933
2018-03-27 4 DIKER CHARLES M S D 113.1481 -2,584 3,690,827 417,610,062
2018-03-23 4 Clifford Peter G F D 113.03 -804 15,422
2018-03-13 4 DIKER CHARLES M S D 115.4889 -9,500 3,693,411 426,547,974
2018-03-12 4 DIKER CHARLES M S D 117.0974 -9,000 3,702,911 433,601,251
2018-03-09 4 DIKER CHARLES M S D 119.1083 -1,500 3,711,911 442,119,409
2018-01-23 4 NODIFF ERIC W S D 112.2143 -1,000 40,831 4,581,822
2018-01-18 4 Diker Mark N. S D 112.0895 -2,000 471,122 52,807,829
2018-01-17 4 Diker Mark N. S D 111.556 -3,000 473,122 52,779,598
2018-01-16 4 DIKER CHARLES M S D 110.9564 -10,000 3,713,411 412,026,716
2018-01-11 4 DIKER CHARLES M S D 107.2575 -5,700 3,723,411 399,363,755
2018-01-09 4 DIKER CHARLES M S D 107.0541 -4,278 3,729,111 399,216,622
2018-01-03 4 Donnelly-Brienza Dorothy A F D 101.35 -533 4,777
2017-12-29 4 Yellin Seth M S D 103.5764 -1,000 22,856 2,367,342
2017-12-28 4 BATKIN ALAN R G D -10,000 54,225
2017-12-27 4 DIKER CHARLES M S D 102.421 -3,000 3,086,386 316,110,741
2017-12-26 4 DIKER CHARLES M By custodial accounts for benefit of grandchildren G I 1,040 115,924
2017-12-26 4 DIKER CHARLES M G D -1,300 511,098
2017-12-26 4 DIKER CHARLES M By wife G I -1,300 511,098
2017-12-26 4 DIKER CHARLES M S D 102.1019 -5,000 3,090,686 315,564,913
2017-12-22 4 DIKER CHARLES M S D 101.1022 -10,000 3,095,686 312,980,665
2017-10-30 4 DIKER CHARLES M By trust for benefit of children J I -106,000 137,701
2017-12-26 4 Diker Mark N. By custodial account for children G I 520 47,724
2017-12-26 4 Diker Mark N. G D 260 428,398
2017-12-21 4 Diker Mark N. G D -1,459 428,138
2017-12-21 4 BATKIN ALAN R G D -7,000 64,225
2017-12-19 4 DIKER CHARLES M S D 100.4299 -2,000 3,858,949 387,553,862
2017-12-18 4 DIKER CHARLES M S D 100.5447 -10,000 3,860,949 388,197,959
2017-12-18 4 FOTIADES GEORGE L S D 101.085 -5,700 94,366 9,538,987
2017-10-23 4 NODIFF ERIC W G D -177 41,831
2017-10-18 4 DIKER CHARLES M F D 95.42 -613 3,870,949
2017-10-20 4 NODIFF ERIC W By wife S I 97.545 -2,868 42,008 4,097,670
2017-10-16 4 Yellin Seth M F D 96.46 -442 23,856
2017-10-13 4 FOTIADES GEORGE L S D 95.231 -6,000 100,066 9,529,385
2017-10-12 4 Yellin Seth M F D 95.07 -555 24,298
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Motus Could Get Knocked When Lockup Expires

2018-08-07 seekingalpha
When MOTS' 180 lockup period expires on August 13th, pre-IPO shareholders and company insiders will be able to sell more than 10 million currently-restricted shares. (3-1)

20 Massively Underpriced Stocks Wall Street Expects to Soar

2018-06-25 investorplace
Wall Street doesn’t always get it right, but analysts’ track record is better than some skeptics suggest. And when the Street as a whole is arguing for big upside, investors should at least consider what those analysts have to say. (982-13)

Buy Cantel Medical, A High Quality Growth Story

2018-06-18 seekingalpha
Cantel Medical (CMD) is a high quality growth company that is likely to significantly grow its earnings over the next 5 years. The company supplies a diverse set of very stable and growing medical end-markets. The company has a strong track record of generating organic growth but has also demonstrated an ability to grow inorganically through bolt-on acquisitions. (20-0)

New And Old Investing Stories To Be Told

2018-06-01 seekingalpha
This week's Editor's Notes covers a few ideas on the long side that tend to appeal to value investors - the insurance company, the holding company, international growth. (53-0)

Cantel Medical Corporation (CMD) CEO Jorgen Hansen on Q3 2018 Results - Earnings Call Transcript

2018-05-31 seekingalpha
Greetings and welcome to the Cantel Medical Corp Third Quarter 2018 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Milicent Brooks, Head of Corporate Communications at Cantel Medical. Thank you, Ms. Brooks. You may begin. (8-1)